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Background
Recent literature data reported evidence of the visual and/or 
anatomical benefits of all clinically available anti-VEGF drugs for 
the treatment of macular edema (ME) following Central Retinal 
Vein Occlusion (CRVO), up to 1-year follow-up [1-3]. Moreover, 
both ranibizumab and pegaptanib sodium have been effective in 
refractory CRVO-ME or BRVO-ME case series of patients who had 
previous bevacizumab and/or triamcinolone injections [4,5]. There 
are no randomized clinical trial data on anti-VEGF agents in ischemic 
subgroup CRVO-ME and the use of anti-VEGF agents to treat this 
condition therefore remains anedoctal. 
Case Presentation
A 73-year old caucasian man, with a general medical history of 
diabetes and systemic hypertension and an ophthalmic history of 
non-ischemic Central Retinal Vein Occlusion (CRVO) with cystoid 
macular edema (CME) in his right eye in December 2008, was 
referred to our division on January 2011. The patient had undergone 
3 triamcinolon injections in 2009 and a Panretinal Photocoagulation 
after an ischemic shift. The ophthalmic examination showed in this eye 
a visual acuity of 20/2000, a C2N1 cataract (based on Lens Opacities 
Classification System III) and an exudative macular detachment. 
The left eye was normal with a visual acuity of 20/20. We performed 
fluorescein angiography and Optical Coherence Tomography (OCT3 
Stratus, Carl Zeiss, Dublin, CA), the latter showing a foveal thickness 
of 1718 µm, measured by caliper (Figures 1 and 2). On 02/09/2011, 
once obtained the informed consent, a 0.5 mg ranibizumab intravitreal 
injection (Lucentis®, Novartis, Basel, Switzerland) was carried out in 
the right eye. 15 and 25 days later, we repeated the OCT, that showed 
no changes; the visual acuity was unchanged as well. Due to the 
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Abstract
Recent literature data reported evidence of the visual and/or anatomical benefits of all clinically available anti-VEGF 
drugs for the treatment of macular edema (ME) following Central Retinal Vein Occlusion (CRVO), up to 1-year follow-
up. There are no randomized clinical trial data on anti-VEGF agents in ischemic CRVO-ME and the use of anti-VEGF 
agents to treat this condition. 
A 73-year old caucasian man, with a medical history of diabetes and systemic hypertension and an ophthalmic 
history of ischemic CRVO with cystoid macular edema was referred to our division on January 2011. The ophthalmic 
examination showed in right eye a visual acuity of 20/2000, a C2N1 cataract and an exudative macular detachment. 
On February 2011, a 0.5mg ranibizumab intravitreal injection (Lucentis®, Novartis, Basel, Switzerland) was carried out 
in the right eye. 15 and 25 days later the OCT showed no changes. On March 2011, we performed a 0.3mg pegaptanib 
sodium intravitreal injection (Macugen, Eyetech Pharmaceuticals, Inc. and Pfizer Inc, New York, NY) in the right eye 
and 15 days later the fluorescein angiography and the OCT examination showed reabsorption of subretinal fluid, 
complete disappearing of macular detachment and normalization of foveal profile, with a thickness of 240 µm and visual 
acuity of 20/400. Three months later, foveal profile and visual acuity were unchanged.
In our refractory ischemic CRVO-ME patient, pegaptanib sodium showed prompt clinical response. In some cases, 
even if it is selective for the VEGF165 isoform only, pegaptanib sodium could represent a further possibility in such a 
therapeutic challenge.
Figure 1: Fluorescein angiography at baseline.
patient’s demands, and on the basis of the usually rapid improvement, 
within 7 days, in visual acuity and foveal thickness in the CRUISE study 
(ranibizumab), and of the small series from Udaondo et al. [3,5] on 
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pegaptanib efficacy, on 03/09/2011, after the written informed consent, 
we switched to a 0.3 mg pegaptanib sodium intravitreal injection 
(Macugen, Eyetech Pharmaceuticals, Inc. and Pfizer Inc, New York, 
NY) in the right eye and 15 days later the fluorescein angiography 
and the OCT examination showed reabsorption of subretinal fluid, 
complete disappearing of macular detachment and normalization of 
foveal profile, with a foveal thickness of 240 µm and visual acuity of 
20/400 (Figures 3 and 4). Three months later, foveal profile and visual 
acuity were unchanged.
Conclusion
It is difficult to individuate if the lack of efficacy of ranibizumab in 
this case is due to the block of the neuroprotectant isoforms of VEGF 
necessary for the adaptative response of retinal neurons to ischemic 
injury or if another “trigger” is involved with the pegaptanib response. 
Anyway, the observation that, in our refractory ischemic CRVO-
ME patient, pegaptanib sodium showed prompt clinical response, may 
suggest that at least in some cases this drug could represent a further 
possibility in such a therapeutic challenge.
Moreover, even if today dexamethasone intravitreal implant has 
a specific indication for the treatment of macular edema following 
CRVO, anti-VEGF therapy could well maintain a role due to minimal 
collateral effects, at least for glaucoma patients or in combination 
treatments. 
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Figure 2: Optical Coherence Tomography (OCT3 Stratus, Carl Zeiss, Dublin, 
CA) at baseline.
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Figure 4: Optical Coherence Tomography (OCT3 Stratus, Carl Zeiss, Dublin, 
CA) at 15 days follow-up.
Figure 3: Fluorescein angiography at 15 days follow-up.
